Cargando…

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS

KRAS mutations in non-small-cell lung cancer (NSCLC) patients are considered a negative predictive factor and indicate poor response to anticancer treatments. KRAS mutations lead to activation of the PI3K/akt/mTOR pathway, whose inhibition remains a challenging clinical target. Since the PI3K/akt/mT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caiola, Elisa, Brunelli, Laura, Marabese, Mirko, Broggini, Massimo, Lupi, Monica, Pastorelli, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239488/ https://www.ncbi.nlm.nih.gov/pubmed/27283493 http://dx.doi.org/10.18632/oncotarget.9849

Ejemplares similares

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation
por: Caiola, Elisa, et al.
Publicado: (2020)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
por: Colombo, Marika, et al.
Publicado: (2022)

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
por: Caiola, Elisa, et al.
Publicado: (2018)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

It’s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?
por: Caiola, Elisa, et al.
Publicado: (2020)

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
por: Arbour, Kathryn C., et al.
Publicado: (2021)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Targeting the PI3K signaling pathway in KRAS mutant colon cancer
por: Hong, Suntaek, et al.
Publicado: (2015)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
por: Zhou, Fei, et al.
Publicado: (2015)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_djadvmq2nh2gk0ehfaof907her